Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase 2/3 1Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia 1Congenital Abnormalities 1

Interventions

Cyclophosphamide 34fludarabine phosphate 33Cytarabine 33fludarabine 26Peripheral Blood Stem Cell Transplantation 23Filgrastim 23Methotrexate 18Busulfan 17Rituximab 15Cyclosporine 14Azacitidine 14Melphalan 13Clofarabine 13Tacrolimus 12venetoclax 11Mycophenolic Acid 10Etoposide 10Alemtuzumab 10Radiotherapy 9Imatinib Mesylate 8Granulocyte Colony-Stimulating Factor 8Decitabine 8ruxolitinib 7Whole-Body Irradiation 7Stem Cell Transplantation 7Idarubicin 7Dexamethasone 7Antilymphocyte Serum 7aldesleukin 6Mitoxantrone 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Leukemia × Amsacrine × Clear all
NCT00840684 2011-05-13

Laromustine, Daunorubicin, and Cytarabine in Treating Patients With Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 1/2 Completed
135 enrolled
Other hematologic neoplasm

Congenital Abnormalities, Leukemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡